Badanie bezpieczeństwa i skuteczności MK-6070 w połączeniu z innymi lekami u pacjentów z rozległym drobnokomórkowym rakiem płuca (pierwsza linia)

Confirmation of eligibility and baseline examinations

After joining the study you will undergo a series of baseline examinations that may include physical Examination, blood tests, and imaging studies to document the extent of small cell lung cancer.

The study team will confirm that the inclusion Criteria are MET and that no exclusion Criteria are present before any study medication is given.

Initiation of study medication

The first dose of the investigational drugs is administered by intravenous infusion in a clinical setting.

The medications used in the study are MK-6070 (gocatamig) and ifinatamab deruxtecan (i-DXd). both are given as an infusion; specific dose, frequency, and total duration are defined by the study protocol and will be followed throughout the treatment period.

Repeated treatment cycles

Subsequent infusions of MK-6070 and ifinatamab deruxtecan are given at regular intervals according to the protocol, typically every three weeks, until the planned number of cycles is completed or until discontinuation Criteria are MET.

Each infusion session includes monitoring of vital signs and observation for immediate reactions.

Concomitant background or comparator therapy (if assigned)

Depending on the treatment arm, additional medications may be administered, such as atezolizumab, tocilizumab, etoposide, or carboplatin. these drugs are also given by intravenous infusion and follow the dosing schedule defined in the protocol.

Regular safety and efficacy assessments

Throughout the treatment period you will have scheduled visits for blood tests, physical examinations, and imaging studies to evaluate safety and tumor response.

The primary efficacy measure is the objective response rate, assessed by imaging according to RECIST 1.1 criteria.

Criteria for treatment discontinuation

Treatment may be stopped early if a dose‑limiting toxicity occurs, if you experience a serious adverse event, or if disease progression is documented.

The decision to discontinue is made by the study physician based on predefined Criteria.

End‑of‑treatment evaluation

After the final planned infusion a comprehensive evaluation is performed, including final imaging and laboratory tests to document the overall response and any lasting side effects.

Follow‑up period

Following the end of treatment you will be followed for a period of time to monitor long‑term safety and survival outcomes.

Follow‑up visits may occur every few months and include basic clinical assessments.